SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

SNDL Inc.NASDAQ: SNDL

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of CA$4K fell 96.0% year over year, behind the -3.9% change in trailing-twelve-month research & development. Sequentially, it fell 97.0% from the prior quarter. Over 3 fiscal years it compounded at -41.5% a year.

Context

  • Research & development amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -96.0% toward the trailing-twelve-month pace of -3.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$4K-97.0% QoQ
Last fiscal yearDec 2025
CA$489K+41.3% YoY
LTMMar 2026
CA$393K-3.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-96.0%——
1 year+41.3%——
3-year CAGR-41.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

CAD · from the income statement

Latest · FY2025
489K CAD
Year-over-year change
+41.3%
4-year CAGR
-33.1%

Research & Development vs competitors

How SNDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -3.9% is the 8th highest of 11, against a peer median of +2.6%.
  • Research & development amounts to 0.0% of revenue for SNDL, versus a peer median of 10.6%.
SNDL Competitors
Research & Development for SNDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SIGASIGA Technologies, Inc.LTM Mar 2026$2.7T USD+25130615.4%-33.8%2884018.5%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$176.31M USD+40.8%+24.2%—
CMPSCOMPASS Pathways plcLTM Mar 2026$110.07M USD-12.0%+22.1%—
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$67.09M USD+78.1%-27.8%28.9%
EBSEmergent BioSolutions Inc.LTM Mar 2026$49.1M USD-30.6%-34.1%7.3%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$49.06M USD+2.0%+3.9%9.6%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$44.28M USD-2.4%-26.2%10.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$37.44M USD+64.5%+11.3%—
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$16.04M USD-18.6%-0.6%31.9%
EOLSEvolus, Inc.LTM Mar 2026$9.6M USD+3.2%+12.4%3.2%
SNDLSNDL Inc.LTM Mar 2026CA$393K CAD-3.9%-41.5%0.0%
Peer median (excluding SNDL) —+2.6%+1.7%10.6%

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.13M712.2M909.01M920.45M946.4M
Cost of Revenue65.13M571.82M718.59M680.12M687.75M
Gross Profit(9M)140.38M190.42M240.33M258.65M
Gross Margin-16.0%19.7%20.9%26.1%27.3%
Research & Development2.45M2.45M324K346K489K
Selling, General & Admin55.39M158.26M230.17M219.28M210.63M
Operating Expenses125.38M488.15M353.59M344.14M263.07M
Depreciation & Amortization10.16M47.32M64.95M56.71M56.27M
EBITDA(223.76M)(326.55M)(99.15M)(41.2M)48.02M
EBITDA Margin-398.7%-45.9%-10.9%-4.5%5.1%
Operating Income(134.38M)(347.77M)(163.17M)(103.81M)(4.42M)
Operating Margin-239.4%-48.8%-18.0%-11.3%-0.5%
Interest Income13.72M17.62M15.37M16.4M8.05M
Interest Expense776K5.9M7.92M7.7M7.52M
Other Income / Expenses(100.32M)(32M)(8.85M)(1.8M)(11.35M)
Income Before Tax(234.7M)(379.77M)(172.02M)(105.61M)(15.77M)
Pre-Tax Margin-418.1%-53.3%-18.9%-11.5%-1.7%
Income Tax Expense(7.91M)(7.34M)0(9.41M)0
Net Income(226.98M)(335.11M)(172.66M)(94.8M)(15.77M)
Net Margin-404.4%-47.1%-19.0%-10.3%-1.7%
EPS (Basic)(1.24)(1.50)(0.65)(0.38)(0.06)
EPS (Diluted)(1.24)(1.50)(0.65)(0.38)(0.06)
Weighted Avg Shares186.04M229.87M259.37M264.2M258.05M
Weighted Avg Shares (Diluted)186.04M229.87M259.37M264.2M258.05M

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.